GlassScriptPhysician profile
Marina Plon
NPI 1366531667
$11,505.61
in general payments reported to CMS, 2019-2025
44 companies · $2,283 in 2025
The $2,283 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $307 · 2021: $1,225 · 2022: $2,184 · 2023: $2,333 · 2024: $1,491 · 2025: $2,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,876 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,876.44 |
| Education | $230.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,092.82 | 2019-2025 | Cardiomems, Gallant |
| Novartis Pharmaceuticals Corporation | $1,449.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $917.34 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $833.48 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $518.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.60 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $402.19 | 2021-2022 | |
| Novo Nordisk INC | $372.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $325.73 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $294.98 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $270.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.10 | 2019-2025 | Jardiance |
| Amgen INC. | $267.14 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $236.63 | 2019-2025 | Farxiga |
| Bridgebio Pharma, INC. | $229.11 | 2025 | Attruby |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Plon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.